PGD is an advanced technology that allows genetic analysis of embryos to screen for aneuploidies (chromosomal abnormalities) and specific genetic disorders. For PGD, a biopsy is performed on the embryo on day 5, and the collected cells are sent to the genetic laboratory for analysis. Based on the results, a suitable embryo can be transferred to the patient on the same day. Since PGD screens a limited number of chromosomes, it provides results in a shorter time and is more cost-effective.
PGD, increasingly used worldwide and in our country among IVF patients, is especially recommended for couples with a high risk of creating embryos with chromosomal abnormalities, such as:
Advanced maternal age
Family history of sex chromosome-linked disorders
Recurrent miscarriages
Repeated unsuccessful IVF attempts
Chromosomal abnormalities in parents (translocations, inversions, etc.)
Previous pregnancy with chromosomal abnormalities
On the day of egg retrieval, sperm cells taken from the male partner are injected directly into the eggs using the ICSI technique. The fertilized eggs are monitored in the laboratory, and on day 3, a biopsy is taken from each embryo for analysis. After screening, healthy embryos are identified, and the transfer of the selected embryo into the uterus completes the treatment.
PGD is also frequently used for determining sex chromosomes within a short timeframe.
It is important to note that even if the patient has previously conceived or given birth, pregnancy is never guaranteed to be 100%. Success rates vary depending on the woman’s age, egg count, and embryo quality.
Stay Healthy,
Cyprus American IVF Center
